Impact of 1-Year Supplementation with High-Rich Docosahexaenoic Acid (DHA) on Clinical Variables and Inflammatory Biomarkers in Pediatric Cystic Fibrosis: A Randomized Double-Blind Controlled Trial

Impact of 1-Year Supplementation with High-Rich Docosahexaenoic Acid (DHA) on Clinical Variables and Inflammatory Biomarkers in Pediatric Cystic Fibrosis: A Randomized Double-Blind Controlled Trial

A randomized, double-blind, and placebo-controlled study was conducted to assess the effect of dietary supplementation with high-rich docosahexaenoic acid (DHA) (Tridocosahexanoin-AOX<sup>®</sup> 70%) at 50 mg/kg/day in pediatric patients with cystic fibrosis (CF) as compared with placeb...

Full description

Bibliographic Details
Main Authors: Roser Ayats-Vidal, Montserrat Bosque-García, Begoña Cordobilla, Oscar Asensio-De la Cruz, Miguel García-González, Susana Loureda-Pérez, Elena Fernández-López, Eva Robert-Barriocanal, Andrea Valiente-Planas, Joan Carles Domingo
Format: Article
Language:English
Published: MDPI AG 2024-03-01
Series:Nutrients
Subjects:
cystic fibrosis
omega-3 fatty acids
docosahexaenoic acid
pulmonary function
inflammatory biomarkers
randomized controlled trial
Online Access:https://www.mdpi.com/2072-6643/16/7/970

Internet

https://www.mdpi.com/2072-6643/16/7/970

Similar Items